<DOC>
	<DOCNO>NCT00590720</DOCNO>
	<brief_summary>The main objective study evaluate safety tolerability multiple fixed dos MEDI-528 adult patient stable asthma exercise-induced bronchoconstriction ( EIB ) .</brief_summary>
	<brief_title>A Phase 2A Study Evaluate Safety Effect Exercise Challenge Testing MEDI-528 Adults With Asthma</brief_title>
	<detailed_description>The primary objective study evaluate safety tolerability multiple fix escalate SC dose MEDI-528 adult patient stable asthma exercise-induced bronchoconstriction ( EIB ) .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Patients must meet following criterion : Male female adult , age 18 50 year time screening ; Weight 50100 kg body mass index ≤ 35 ; Written inform consent obtain patient prior receipt study medication begin study procedure ; Documented clinical history asthma receive stable treatment ≥ 1 month prior Study Day 0 ; Airway hyperresponsiveness ( AHR ) methacholine inhalation challenge test screening ( documented history within past 6 month ) , provoke concentration methacholine cause 20 % fall FEV1 ( subscript ) ( PC20 ) ≤ 8 mg/mL ( Crapo , 2000 ) ; Exerciseinduced bronchoconstriction ( EIB ) decrease FEV1 ( subscript ) ≥ 15 % preexercise challenge test level screening ; Able provide spirometry reading meet American Thoracic Society ( ATS ) European Respiratory Society ( ERS ) standard ( Miller , 2005 ) ; Women childbearing potential , unless surgically sterile least 1 year postmenopausal , must use two effective method avoid pregnancy ( include oral , transdermal , implanted contraceptive , intrauterine device , female condom , spermicide , diaphragm , cervical cap , abstinence , contraceptive foam , use condom sexual partner sterile sexual partner ) screening Study Day 0 , must agree continue use precaution Study Day 150 . Cessation birth control point discuss responsible physician . Men , unless surgically sterile , must likewise use effective method birth control ( condom spermicide ) must agree continue use precaution screen Study Day 150 ; Able complete study period , include followup period , approximately 150 day ; Willing forego form experimental treatment study procedure study 30 day followup period complete . Patients must none follow criterion : Receipt MEDI528 previous clinical study ; History allergy reaction component study drug formulation ; Lung disease asthma ( eg , chronic obstructive pulmonary disease , cystic fibrosis ) ; Forced expiratory volume 1 second ( FEV1subscript ) &lt; 70 % predict value screen ; Use systemic immunosuppressive drug include systemic corticosteroid , ICS dose &gt; 800 μg/day budesonide ( another ICS equivalent dose ) , longacting β2 agonist , cromolyn sodium , nedocromil sodium , leukotriene receptor antagonist , theophylline , omalizumab screen Study Day 150 ; Current use βadrenergic antagonist ( eg , propranolol ) ; Any disease illness , asthma , likely require use systemic corticosteroid study period ; Acute illnesses evidence significant active infection , fever ≥ 38.0°C ( 100.5°F ) screening Study Day 0 ; Current allergy vaccination therapy ( desensitization immunotherapy ) ; Receipt investigational drug therapy within 30 day biologic ( ) within 5 halflives agent prior screen ; Pregnancy ( woman child bear potential , unless surgically sterile least 1 year postmenopausal , must negative serum urine pregnancy test screen methacholine inhalation challenge test negative urine pregnancy test prior study drug administration Study Day 0 ) ; Breastfeeding lactate woman ; Evidence infection hepatitis B C virus HIV1 HIV2 , active infection hepatitis A ; must negative HIV1 , HIV2 , hepatitis A , B , C test screen ; History cancer basal cell carcinoma skin cervical carcinomainsitu treat apparent success curative therapy 1 year prior Study Day 0 ; History primary immunodeficiency History pancreatitis currently active gastroduodenal ulcer ; Current use tobacco product history use tobacco product one cigarette per month equivalent within 1 year prior randomization history smoke ≥ 10 packyears ; History lifelong urinary retention ; History anaphylaxis ( define immediate lifethreatening event require medical invention ) ; Elective surgery plan screen Study Day 150 ; Clinically significant abnormality , determine investigator , 12lead ECG chest radiograph screening ; History disease , evidence current disease ( asthma ) , find upon physical examination , laboratory abnormality , , opinion investigator medical monitor , may compromise safety patient study confound analysis study ; Any employee research site involve conduct study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Bronchitis</keyword>
</DOC>